Literature DB >> 28395861

Dissemination and clinical implications of multidrug-resistant Klebsiella pneumoniae isolates producing OXA-48 in a Spanish hospital.

A Madueño1, J González García2, S Fernández-Romero3, J Oteo3, M Lecuona4.   

Abstract

BACKGROUND: Healthcare-associated infections caused by Klebsiella pneumoniae isolates are increasing and few effective antibiotics are currently available to treat patients. AIM: To assess the epidemiology, molecular basis, clinical features, and outcomes in the acquisition and dissemination of OXA-48-producing K. pneumoniae (OXA48KP) in a tertiary Spanish hospital between October 2013 and December 2015.
METHODS: Clinical, demographic, and microbiological data of patients with OXA48KP in clinical samples were collected from medical records. Carbapenemase genes were detected by polymerase chain reaction. Genetic relationships were determined by pulsed-field gel electrophoresis and multi-locus sequence typing.
FINDINGS: In all, 116 episodes of OXA48KP in clinical samples were identified. The most frequent types of infection were urinary tract (N = 43, 42%), secondary bloodstream (N = 18, 17%), and surgical site infection (N = 17, 17%). More than one-quarter (28%) of infected patients died in hospital. Among infected patients (N = 90, 78%), infections were mainly classified as hospital-acquired (N = 70, 88%). A high number of OXA48KP isolates showed multidrug resistance, with highest susceptibility to colistin (86%), gentamicin (69%) and amikacin (59%). Most (87%) isolates were included in a main cluster. Seven (N = 8, 88%) isolates showed an identical allelic profile, associated with ST15. Only the isolate from cluster P8 was associated with ST29. The results confirm high dissemination of OXA48KP in our hospital due to the main clone ST15. OXA48KP infection was associated with a high mortality and was mainly hospital-acquired.
CONCLUSION: This study highlights the importance of active surveillance programmes, especially those focusing on hospital readmissions in order to control the spread of carbapenemase-producing Enterobacteriaceae.
Copyright © 2017 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Infection; Klebsiella pneumoniae; OXA-48

Mesh:

Substances:

Year:  2017        PMID: 28395861     DOI: 10.1016/j.jhin.2017.02.024

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  8 in total

1.  Prevalence and Characterisation of Multiresistant Bacterial Strains Isolated in Pigs from the Island of Tenerife.

Authors:  Rossana Abreu; Cristobalina Rodríguez-Álvarez; Beatriz Castro-Hernandez; Maria Lecuona-Fernández; Juan Carlos González; Yurena Rodríguez-Novo; Maria de Los Angeles Arias Rodríguez
Journal:  Vet Sci       Date:  2022-06-03

Review 2.  Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens.

Authors:  Flora Cruz-López; Adrian Martínez-Meléndez; Rayo Morfin-Otero; Eduardo Rodriguez-Noriega; Héctor J Maldonado-Garza; Elvira Garza-González
Journal:  Front Cell Infect Microbiol       Date:  2022-05-20       Impact factor: 6.073

Review 3.  OXA-48-like carbapenemases producing Enterobacteriaceae in different niches.

Authors:  Assia Mairi; Alix Pantel; Albert Sotto; Jean-Philippe Lavigne; Aziz Touati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-08       Impact factor: 3.267

4.  In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.

Authors:  Krystyna M Kazmierczak; Patricia A Bradford; Gregory G Stone; Boudewijn L M de Jonge; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

5.  Molecular and phenotypic characterization of clinical isolates belonging to a KPC-2-producing strain of ST15 Klebsiella pneumoniae from a Vietnamese pediatric hospital.

Authors:  Björn Berglund; Ngoc Thi Bich Hoang; Maria Tärnberg; Ngai Kien Le; Maud Nilsson; Dung Thi Khanh Khu; Olov Svartström; Jenny Welander; Lennart E Nilsson; Linus Olson; Tran Minh Dien; Hai Thanh Le; Mattias Larsson; Håkan Hanberger
Journal:  Antimicrob Resist Infect Control       Date:  2019-10-16       Impact factor: 4.887

6.  Characterization of Carbapenem-Resistant Klebsiella pneumoniae ST15 Clone Coproducing KPC-2, CTX-M-15 and SHV-28 Spread in an Intensive Care Unit of a Tertiary Hospital.

Authors:  Yaping Han; Lei Huang; Chengcheng Liu; Xu Huang; Ruiying Zheng; Yanfei Lu; Wenying Xia; Fang Ni; Yaning Mei; Genyan Liu
Journal:  Infect Drug Resist       Date:  2021-03-03       Impact factor: 4.003

7.  [Risk factors and clinical evolution of carbapenemase-producing Klebsiella pneumoniae infections in a university hospital in Spain. Case-control study].

Authors:  V Rojo; P Vázquez; S Reyes; L Puente Fuertes; M Cervero
Journal:  Rev Esp Quimioter       Date:  2018-09-18       Impact factor: 1.553

8.  Clinical and Molecular Description of a High-Copy IncQ1 KPC-2 Plasmid Harbored by the International ST15 Klebsiella pneumoniae Clone.

Authors:  Willames M B S Martins; Marisa F Nicolas; Yang Yu; Mei Li; Priscila Dantas; Kirsty Sands; Edward Portal; Luiz G P Almeida; Ana Tereza R Vasconcelos; Eduardo A Medeiros; Mark A Toleman; Timothy R Walsh; Ana C Gales; Diego O Andrey
Journal:  mSphere       Date:  2020-10-07       Impact factor: 4.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.